Embedded Files
Pharmacologic Category
Dosing: Adult
Note: Discontinue when control achieved; if improvement not seen within 2 weeks, reassessment of diagnosis may be necessary.
Mild to moderate plaque-type psoriasis of nonscalp areas: Topical: Foam: Apply twice daily for up to 2 weeks (maximum dose: 50 g/week).
Moderate to severe plaque-type psoriasis: Topical:
Cream (0.025%), emollient cream, lotion: Apply twice daily for up to 2 weeks (cream) or up to 4 weeks if needed (emollient cream, lotion) when application is <10% of body surface area (maximum dose: 50 g/week or 50 mL/week). Treatment with lotion beyond 2 weeks should be limited to localized lesions (<10% body surface area) that have not improved sufficiently.
Spray: Apply by spraying directly onto affected area twice daily and gently rub into skin. Limit treatment to 4 consecutive weeks; treatment beyond 2 weeks should be limited to localized lesions that have not improved sufficiently. Maximum total dose: 50 g/week or 59 mL/week. Do not use more than 26 sprays per application or 52 sprays per day.
Oral mucosal inflammation (off-label use): Topical: Cream: Apply twice daily for up to 2 weeks (maximum dose: 50 g/week); discontinue application when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.
Scalp psoriasis, moderate to severe: Topical:
Foam: Apply twice daily for up to 2 weeks (maximum dose: 50 g/week).
Shampoo: Apply thin film to dry scalp once daily (maximum dose: 50 g/week or 50 mL/week); leave in place for 15 minutes, then add water, lather, and rinse thoroughly. Limit treatment to 4 consecutive weeks.
Steroid-responsive dermatoses: Topical: Cream (0.05%), emollient cream, emollient foam, foam, gel, lotion, ointment, solution: Apply twice daily for up to 2 weeks (maximum dose: 50 g/week or 50 mL/week).
* See Dosage and Administration in AHFS Essentials for additional information.
Dosing: Geriatric
Refer to adult dosing.
Dosing: Renal Impairment: Adult
There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Hepatic Impairment: Adult
There are no dosage adjustments provided in the manufacturer's labeling.
Dosing: Pediatric
Note: Dosage should be based on severity of disease and patient response; use the smallest amount for the shortest period of time to avoid HPA axis suppression; discontinue therapy when control is achieved; reassess diagnosis if no improvement is seen within 2 weeks. Due to the high incidence of adrenal suppression noted in clinical studies, clobetasol lotion, shampoo, and spray are not recommended for use in patients <18 years of age.
Dermatoses (steroid-responsive):
Cream 0.05%, emollient cream, gel, ointment: Children ≥12 years and Adolescents: Topical: Apply sparingly to affected area twice daily for up to 2 weeks; maximum weekly dose: 50 g/week.
Emollient foam: Children ≥12 years and Adolescents: Topical: Apply a thin layer to affected area twice daily in the morning and evening for up to 2 weeks; maximum weekly dose: 50 g/week.
Lotion: Adolescents ≥18 years: Topical: Apply twice daily for up to 2 weeks; maximum weekly dose: 50 g/week or 50 mL/week.
Solution: Children ≥12 years and Adolescents: Topical: Apply sparingly to affected area of scalp twice daily for up to 2 weeks; maximum weekly dose: 50 mL/week.
Plaque-type psoriasis of nonscalp areas, mild to moderate: Children ≥12 years and Adolescents: Foam: Topical: Apply thin layer to affected area twice daily for up to 2 weeks; maximum weekly dose: 50 g/week or 21 capfuls/week.
Plaque-type psoriasis, moderate to severe:
Cream 0.025%: Adolescents ≥18 years: Topical: Apply thin layer twice daily for up to 2 weeks; maximum weekly dose: 50 g/week.
Emollient cream: Adolescents ≥16 years: Topical: Apply sparingly twice daily for up to 2 weeks; if response is not adequate, may be used for up to 2 more weeks if application is <10% of BSA; use with caution; maximum weekly dose: 50 g/week.
Lotion: Adolescents ≥18 years: Topical: Apply twice daily for up to 2 weeks; may extend treatment for an additional 2 weeks for localized lesions <10% of BSA; maximum weekly dose: 50 g/week or 50 mL/week.
Spray: Adolescents ≥18 years: Apply by spraying directly onto affected area twice daily and gently rub into skin for up to 4 weeks; treatment beyond 2 weeks should be limited to localized lesions which have not improved sufficiently. Maximum weekly dose: 50 g/week or 59 mL/week. Do not use more than 26 sprays per application or 52 sprays per day.
Scalp psoriasis, moderate to severe:
Foam: Children ≥12 years and Adolescents: Topical: Apply thin layer twice daily for up to 2 weeks; maximum weekly dose: 50 g/week or 21 capfuls/week.
Shampoo: Adolescents ≥18 years: Topical: Apply thin film to affected area of dry scalp once daily for up to 4 weeks; maximum weekly dose: 50 g/week or 50 mL/week.
Dosing: Renal Impairment: Pediatric
There are no dosage adjustments provided in manufacturer's labeling.
Dosing: Hepatic Impairment: Pediatric
There are no dosage adjustments provided in manufacturer's labeling.
Use: Labeled Indications
Steroid-responsive dermatoses: Short-term relief of inflammation and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses
* See Uses in AHFS Essentials for additional information.
Class and Related Monographs
Administration: Topical
Apply the smallest amount that will cover affected area. For topical use only; avoid contact with eyes and mucous membranes. Do not apply to face, scalp, axilla, groin, or intertriginous areas. Do not use if there is atrophy at the treatment site. Do not cover, bandage, or wrap the treated area unless instructed. Minimize contact to nonaffected areas of the body. Wash hands after use.
Cream, emollient cream, gel, lotion, ointment, solution: Maximum dose: 50 g/week or 50 mL/week.
Emollient foam: Shake can before use. Turn can upside down and spray a small amount (approximately a capful) of foam into the cap. Massage foam into affected area until foam absorbed. Maximum dose: 50 g/week or 21 capfuls/week.
Foam: Turn can upside down and spray a small amount (golf-ball size) of foam into the cap or another cool surface. If the can is warm or foam is runny, place can under cold, running water. If fingers are warm, rinse with cool water and dry prior to handling (foam will melt on contact with warm skin). Massage foam into affected area. Maximum dose: 50 g/week or 21 capfuls/week.
Shampoo: Limit treatment to 4 consecutive weeks. Maximum dose: 50 g/week or 50 mL/week. Use on dry hair; do not wet hair prior to use. Do not use a shower cap or bathing cap while shampoo is on the scalp. Leave in place for 15 minutes, then wet hair, lather and rinse hair and scalp completely. Although no additional shampoo is necessary to cleanse the hair, a nonmedicated shampoo may be used after application if desired.
Spray: Spray directly onto affected area of skin. Gently and completely rub into skin after spraying. Maximum total dose: 50 g/week or 59 mL/week. Do not use more than 26 sprays per application or 52 sprays per day.
Administration: Pediatric
Topical: Apply the smallest amount that will cover affected area. For topical use only; avoid contact with eyes and mucous membranes. Do not apply to face, groin, axillae, diaper area, or intertriginous areas; avoid contact with eyes. Do not use if there is atrophy at the treatment site. Minimize contact to nonaffected areas of the body; wash hands after applying. Occlusive dressings not recommended; do not occlude affected area unless directed by a physician. Not for oral, ophthalmic, or intravaginal use.
Cream, emollient cream, gel, lotion, ointment, solution: Rub in gently and completely.
Emollient foam: Shake can before use. Turn can upside down and spray a small amount of foam into the cap, other cool surface, or to affected area. Massage foam into affected area.
Foam: Turn can upside down and spray a small amount (maximum: 11/2 capful or about the size of a golf ball) of foam into the cap, other cool surface, or to affected area. If the can is warm or foam is runny, place can under cold, running water. If fingers are warm, rinse with cool water and dry prior to handling (foam will melt on contact with warm skin). Massage foam into affected area.
Shampoo: Use on dry scalp; do not wet hair prior to use. Do not use a shower cap or bathing cap while shampoo is on the scalp. Leave in place for 15 minutes, then wet hair, lather, and rinse hair and scalp completely. Although no additional shampoo is necessary to cleanse the hair, a nonmedicated shampoo may be used after application if desired. Avoid contact with eyes and lips.
Spray: Spray directly onto affected area of skin. Gently and completely rub into skin after spraying. Do not use more than 26 sprays per application or 52 sprays per day; refer to product labeling for detailed instructions for use.
Storage/Stability
Cream, emollient cream, lotion, ointment: Store between 15°C to 30°C (59°F to 86°F); do not refrigerate or freeze.
Emollient foam, foam: Store between 20ºC and 25ºC (68ºF and 77ºF); do not expose to temperatures >49°C (120°F). Avoid fire, flame, or smoking during and immediately following application.
Gel: Store between 2°C and 30°C (36°F and 86°F).
Shampoo: Store between 20°C and 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)
Solution: Do not use near an open flame.
Cormax: Store between 15°C to 30°C (59°F to 86°F).
Temovate: Store between 4°C to 25°C (39°F to 77°F).
Spray: Store at room temperature; do not expose to temperatures >30°C (86°F). Do not freeze or refrigerate. Spray is flammable; do not use near open flame.
Medication Patient Education with HCAHPS Considerations
What is this drug used for?
• It is used to treat skin irritation.
• It is used to treat skin rashes.
• It is used to treat scalp psoriasis.
• It is used to treat plaque psoriasis.
Frequently reported side effects of this drug
• Stinging
• Dry skin
• Burning
• Redness
Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:
• High blood sugar like confusion, fatigue, increased thirst, increased hunger, passing a lot of urine, flushing, fast breathing, or breath that smells like fruit
• Cushing syndrome like weight gain in upper back or abdomen; moon face; severe headache; or slow healing
• Adrenal gland problems like severe nausea, vomiting, severe dizziness, passing out, muscle weakness, severe fatigue, mood changes, lack of appetite, or weight loss
• Skin changes like acne, stretch marks, slow healing, or hair growth
• Skin thinning
• Vision changes
• Eye pain
• Severe eye irritation
• Severe skin irritation
• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.
Medication Safety Issues
International issues:
Contraindications
Hypersensitivity to clobetasol, other corticosteroids, or any component of the formulation; primary infections of the scalp (scalp solution only)
Canadian labeling: Additional contraindications (not in US labeling): Treatment of rosacea, acne vulgaris, perioral dermatitis, or perianal and genital pruritus; viral (eg, herpes or varicella) lesions of the skin, bacterial or fungal skin infections, parasitic infections, skin manifestations relating to tuberculosis or syphilis, eruptions following vaccinations; ulcerous wounds; application to eyes or eyelids; children <2 years of age (shampoo); children <1 year of age (cream, ointment, scalp application). Note: Product labels may vary (refer also to product labels).
Warnings/Precautions
Concerns related to adverse effects:
• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.
• Contact dermatitis: Allergic contact dermatitis may occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.
• Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered.
• Local effects: Local effects may occur, including folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae, miliaria, skin atrophy, and telangiectasia; local adverse effects may be irreversible.
• Ocular effects: Topical corticosteroids, including clobetasol, may increase the risk of posterior subcapsular cataracts and glaucoma. Monitor for ocular changes. Avoid contact with eyes.
• Skin infections: Concomitant skin infections may be present or develop during therapy; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.
• Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.
Special populations:
• Pediatric: Use in children <12 years of age is not recommended. Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients. Clobex lotion, Clobex shampoo, Clobex spray, and Clodan shampoo are not recommended for use in patients ≤17 years of age.
Dosage form specific issues:
• Emollient cream: Contains imidurea which releases traces of formaldehyde as a breakdown product; formaldehyde may cause allergic sensitization or irritation upon skin contact.
• Foam/Spray: The foam and spray are flammable. Avoid fire, flame, or smoking during and immediately following application.
Other warnings/precautions:
• Appropriate use: Do not use if there is atrophy at the treatment site. Do not use with occlusive dressing. Do not use on the face, axillae, or groin or for the treatment of acne vulgaris, rosacea, or perioral dermatitis.
* See Cautions in AHFS Essentials for additional information.
Geriatric Considerations
Due to age-related changes in skin, limit use of topical corticosteroids.
Warnings: Additional Pediatric Considerations
The extent of percutaneous absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Infants and small children may be more susceptible to HPA axis suppression, intracranial hypertension, Cushing syndrome, or other systemic toxicities due to larger skin surface area to body mass ratio. Due to the high incidence of adrenal suppression noted in clinical studies, clobetasol lotion, shampoo, and spray are not recommended for use in patients <18 years of age. In a study of patients with moderate to severe atopic dermatitis (involving ≥20% BSA) receiving Clobex 0.05% lotion twice daily for 2 weeks, 9 of the14 pediatric patients (12 to 17 years of age) included developed adrenal suppression, compared to 2 of the 10 pediatric patients receiving the cream. In a study of patients receiving Clobex 0.05% shampoo, 5 of 12 pediatric patients (12 to 17 years of age) developed HPA axis suppression.
Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).
Pregnancy Considerations
Information related to the use of clobetasol in pregnancy is limited (Westermann 2012).
Systemic bioavailability of topical corticosteroids is variable (integrity of skin, use of occlusion, etc.) and may be further influenced by trimester of pregnancy (Chi 2017). In general, the use of topical corticosteroids is not associated with a significant risk of adverse pregnancy outcomes. However, there may be an increased risk of low birth weight infants following maternal use of potent or very potent topical products, especially in high doses. Use of mild to moderate potency topical corticosteroids is preferred in pregnant females and the use of large amounts or use for prolonged periods of time should be avoided (Chi 2016; Chi 2017; Murase 2014). Also avoid areas of high percutaneous absorption (Chi 2017). The risk of stretch marks may be increased with use of topical corticosteroids (Murase 2014).
The treatment of psoriasis in pregnancy is initiated with conservative treatment as in nonpregnant females. When a topical steroid is needed, low to moderate potency corticosteroids are preferred initially. High potency topical steroids should be used only when clearly needed and after the first trimester (Bae 2012).
Breast-Feeding Considerations
Systemic corticosteroids are present in human milk. It is not known if topical application of clobetasol will result in detectable quantities in breast milk.
Information related to the use of clobetasol and breastfeeding is limited (Carrillo Dde 2006). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Low to moderate potency topical corticosteroids are preferred for initial treatment of psoriasis in breastfeeding females (Bae 2012). Do not apply topical corticosteroids to breast until breastfeeding ceases (Leachman 2006); hypertension was noted in a breastfed infant when a high potency topical corticosteroid was applied to the nipple (Butler 2014; Leachman 2006).
Briggs' Drugs in Pregnancy & Lactation
Adverse Reactions
Frequency may depend upon formulation used, length of application, surface area covered, and the use of occlusive dressings.
>10%: Endocrine & metabolic: HPA-axis suppression (13% to 56%)
1% to 10%:
Central nervous system: Localized burning (≤10%), headache (≤2%), numbness of fingers (<2%), local discomfort (1%)
Dermatologic: Skin atrophy (≤4%), telangiectasia (≤3%), eczema (pruritus hiemalis: 2%), xeroderma (≤2%), erythema (<2%), folliculitis (<2%), pruritus (<2%), skin fissure (<2%), stinging of skin (<2%), hypopigmentation (1% to 2%)
Local: Application site reaction (2% to 4%), local irritation (<2%)
Respiratory: Upper respiratory tract infection (8%), nasopharyngitis (5%), streptococcal pharyngitis (1%)
Frequency not defined:
Dermatologic: Local acneiform eruptions, urticaria
Local: Application site edema
<1%, postmarketing, and/or case reports: Alopecia, application site induration, atrophic striae, cataract, contact dermatitis, Cushing syndrome, dermatitis, desquamation, exacerbation of psoriasis, excoriation, exfoliation of skin, eye irritation, glaucoma, hypertrichosis, increased intraocular pressure, indurated plaques of the skin, lichenoid eruption, miliaria, papule, perioral dermatitis, retinopathy (central serous), scalp pustules, scalp tightness, secondary infection, skin pain, skin rash, skin tenderness (scalp), tingling of skin (scalp)
* See Cautions in AHFS Essentials for additional information.
Allergy and Idiosyncratic Reactions
Metabolism/Transport Effects
None known.
Drug Interactions Open Interactions
Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Risk X: Avoid combination
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Risk C: Monitor therapy
Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy
Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Risk D: Consider therapy modification
Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. Risk C: Monitor therapy
Monitoring Parameters
Adrenal suppression with extensive/prolonged use (ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); response to treatment; ocular changes
Advanced Practitioners Physical Assessment/Monitoring
Obtain ACTH stimulation test, morning plasma cortisol test, and urinary free cortisol test in patients with signs of adrenal suppression or with extensive/prolonged use. Assess for ocular changes. Reassess patient for improvement in condition within 2 weeks. Educate patient on proper administration of product. Assess for hyperglycemia and signs of Cushing’s disease. Assess for and evaluate skin changes.
Nursing Physical Assessment/Monitoring
Check ordered labs and report any abnormalities. Monitor for and educate patient to report any skin changes, vision changes, or signs of hyperglycemia (confusion, fatigue, increased thirst, increased hunger, polyuria). Educate patient on proper administration/use.
Dosage Forms: US
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Cream, External, as propionate:
Clobetasol Propionate E: 0.05% (15 g, 30 g, 60 g) [contains cetostearyl alcohol, propylene glycol]
Clobetasol Propionate E: 0.05% (15 g, 30 g, 60 g) [contains propylene glycol]
Impoyz: 0.025% (60 g [DSC], 100 g) [contains cetostearyl alcohol, methylparaben, propylparaben]
Temovate: 0.05% (30 g, 60 g) [contains cetostearyl alcohol, chlorocresol (chloro-m-cresol), propylene glycol]
Temovate E: 0.05% (60 g [DSC])
Generic: 0.05% (15 g, 30 g, 45 g, 60 g)
Foam, External, as propionate:
Olux: 0.05% (50 g [DSC], 100 g [DSC]) [contains cetyl alcohol, propylene glycol]
Olux: 0.05% (50 g, 100 g) [cfc free; contains alcohol, usp, cetyl alcohol, propylene glycol]
Olux-E: 0.05% (50 g [DSC], 100 g [DSC]) [contains cetyl alcohol, propylene glycol]
Olux-E: 0.05% (50 g, 100 g) [cfc free; contains cetyl alcohol, propylene glycol]
Tovet: 0.05% (100 g) [contains cetyl alcohol, propylene glycol]
Generic: 0.05% (50 g, 100 g)
Gel, External, as propionate:
Temovate: 0.05% (60 g [DSC]) [contains propylene glycol]
Generic: 0.05% (15 g, 30 g, 60 g)
Kit, External, as propionate:
Clodan: 0.05% [contains alcohol, usp, cetyl alcohol, edetate disodium, propylene glycol]
Tovet: 0.05% [contains cetyl alcohol, edetate disodium, methylparaben, propylene glycol, trolamine (triethanolamine)]
Liquid, External, as propionate:
Clobex Spray: 0.05% (59 mL, 125 mL) [contains alcohol, usp]
Generic: 0.05% (59 mL, 125 mL)
Lotion, External, as propionate:
Clobex: 0.05% (59 mL, 118 mL)
Generic: 0.05% (59 mL, 118 mL)
Ointment, External, as propionate:
Temovate: 0.05% (15 g, 30 g) [contains propylene glycol]
Generic: 0.05% (15 g, 30 g, 45 g, 60 g)
Shampoo, External, as propionate:
Clobex: 0.05% (118 mL) [contains alcohol, usp]
Clodan: 0.05% (118 mL) [contains alcohol, usp]
Generic: 0.05% (118 mL)
Solution, External, as propionate:
Cormax Scalp Application: 0.05% (50 mL [DSC]) [contains isopropyl alcohol]
Temovate: 0.05% (50 mL [DSC])
Generic: 0.05% (25 mL, 50 mL)
Dosage Forms: Canada
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Cream, External, as propionate:
Dermovate: 0.05% (15 g, 50 g)
Generic: 0.05% (15 g, 30 g, 50 g, 450 g, 454 g)
Foam, External, as propionate:
Olux-E: 0.05% (10 g, 50 g, 100 g) [contains cetyl alcohol, propylene glycol]
Liquid, External, as propionate:
Clobex Spray: 0.05% (59 mL, 125 mL) [contains alcohol, usp]
Generic: 0.05% (59 mL)
Ointment, External, as propionate:
Dermovate: 0.05% (15 g, 50 g)
Generic: 0.05% (15 g, 50 g, 450 g, 454 g)
Shampoo, External, as propionate:
Clobex: 0.05% (15 mL, 118 mL) [contains alcohol, usp]
Solution, External, as propionate:
Dermovate: 0.05% (20 mL, 60 mL)
Generic: 0.05% (20 mL, 59 mL, 60 mL, 90 mL)
Anatomic Therapeutic Chemical (ATC) Classification
- D07AD01
Generic Available (US)
May be product dependent
Pricing: US
Cream (Clobetasol Prop Emollient Base External)
0.05% (per gram): $4.54
Cream (Clobetasol Propionate External)
0.05% (per gram): $1.76 - $8.55
Cream (Impoyz External)
0.025% (per gram): $11.40
Cream (Temovate External)
0.05% (per gram): $10.56
Foam (Clobetasol Propionate Emulsion External)
0.05% (per gram): $7.02
Foam (Clobetasol Propionate External)
0.05% (per gram): $4.17 - $7.02
Foam (Olux External)
0.05% (per gram): $12.87
Foam (Olux-E External)
0.05% (per gram): $12.87
Foam (Tovet External)
0.05% (per gram): $7.64
Gel (Clobetasol Propionate External)
0.05% (per gram): $2.76 - $9.26
Kit (Clodan External)
0.05% (per each): $730.42
Kit (Tovet External)
0.05% (per gram): $2.15
Liquid (Clobetasol Propionate External)
0.05% (per mL): $0.65 - $6.69
Liquid (Clobex Spray External)
0.05% (per mL): $9.00
Lotion (Clobetasol Propionate External)
0.05% (per mL): $4.90 - $7.05
Lotion (Clobex External)
0.05% (per mL): $10.17
Ointment (Clobetasol Propionate External)
0.05% (per gram): $8.27 - $8.66
Ointment (Temovate External)
0.05% (per gram): $12.80
Shampoo (Clobetasol Propionate External)
0.05% (per mL): $1.84 - $7.67
Shampoo (Clobex External)
0.05% (per mL): $8.52
Shampoo (Clodan External)
0.05% (per mL): $6.19
Solution (Clobetasol Propionate External)
0.05% (per mL): $2.40 - $4.13
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Mechanism of Action
Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A2 inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Clobetasol has very high range potency.
Pharmacodynamics/Kinetics
Absorption: Percutaneous absorption is variable and dependent upon many factors including vehicle used, integrity of epidermis, dose, and use of occlusive dressings (not recommended); absorption is increased by occlusive dressings or with decreased integrity of skin (eg, inflammation or skin disease); gel has greater absorption than cream
Metabolism: Hepatic
Excretion: Urine and feces
Dental Use
Short-term relief of oral mucosal inflammation
* See Uses in AHFS Essentials for additional information.
Local Anesthetic/Vasoconstrictor Precautions
No information available to require special precautions
Effects on Dental Treatment
No significant effects or complications reported
Effects on Bleeding
No information available to require special precautions
Dental Usual Dosing
Oral mucosal inflammation: Children ≥12 years and Adults: Cream: Apply twice daily for up to 2 weeks (maximum dose: 50 g/week); discontinue application when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary
Related Information
Index Terms
Clobetasol Propionate
FDA Approval Date
December 27, 1985
References
American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics. 1997;99(2):268-278.[PubMed 9024461]
Bae YS, Van Voorhees AS, Hsu S, et al.; National Psoriasis Foundation. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(3):459-477. doi: 10.1016/j.jaad.2011.07.039.[PubMed 22018758]
Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70(3):417.e1-10; quiz 427. doi: 10.1016/j.jaad.2013.09.009.[PubMed 24528912]
Carrillo Dde L. Vegetating darier's disease during pregnancy. Acta Derm Venereol. 2006;86(3):259-260.[PubMed 16710592]
Chi CC, Kirtschig G, Aberer W, et al. Updated evidence-based (S2e) European Dermatology Forum guideline on topical corticosteroids in pregnancy. J Eur Acad Dermatol Venereol. 2017;31(5):761-773. doi: 10.1111/jdv.14101.[PubMed 28233354]
Chi CC, Wang SH, Kirtschig G. Safety of Topical Corticosteroids in Pregnancy. JAMA Dermatol. 2016;152(8):934-935. doi: 10.1001/jamadermatol.2016.1009.[PubMed 27366995]
Clobetasol propionate emollient cream [prescribing information]. Melville, NY: Fougera Pharmaceuticals Inc; September 2018.
Clobetasol propionate gel [prescribing information]. Buena, NJ: Teligent Pharma Inc; February 2017.
Clobetasol Propionate Topical Solution, USP (0.05%) [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; September 2017.
Clobetasol Propionate Topical Solution, USP (0.05%) [prescribing information]. Morton Grove, IL: Morton Grove Pharmaceuticals, Inc; May 2018.
Clobetasol Propionate Topical Solution, USP (0.05%) [prescribing information]. Fort Collins, CO: Tolmar, Inc; April 2018.
Clobex Lotion (clobetasol) [prescribing information]. Fort Worth, TX: Galderma Laboratories; July 2014.
Clobex Lotion (clobetasol) [prescribing information]. Fort Worth, TX: Galderma Laboratories; February 2018.
Clobex shampoo (clobetasol) [prescribing information]. Fort Worth, TX: Galderma Laboratories; November 2012.
Clobex shampoo (clobetasol) [prescribing information]. Fort Worth, TX: Galderma Laboratories; February 2018.
Clobex Shampoo (clobetasol) [product monograph]. Thornhill, Ontario, Canada: Galderma Canada Inc; January 2020.
Clobex Spray (clobetasol) [product monograph]. Thornhill, Ontario, Canada: Galderma Canada Inc; December 2018.
Clobex Spray (clobetasol) [prescribing information]. Fort Worth, TX: Galderma Laboratories; January 2019.
Clodan (clobetasol) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; January 2016.
Clodan Kit (clobetasol) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; February 2016.
Clodan shampoo (clobetasol) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; December 2017.
Clodan shampoo (clobetasol) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; February 2016.
Cormax (clobetasol) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; April 2014.
Dermovate (clobetasol) cream and ointment [product monograph]. Thornhill, Ontario, Canada: TaroPharma; August 2003.
Dermovate Scalp Application (clobetasol) [product monograph]. Thornhill, Ontario, Canada: TaroPharma; September 2003.
Goedert JJ, Vitale F, Lauria C, et al, “Risk Factors for Classical Kaposi's Sarcoma,” J Natl Cancer Inst, 2002, 94(22):1712-8.[PubMed 12441327]
Impoyz (clobetasol) [prescribing information]. Scottsdale, AZ: Encore Dermatology, Inc; November 2019.
Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin. 2006 Apr;24(2):167-97, vi.[PubMed 16677965]
Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1-14; quiz 415. doi: 10.1016/j.jaad.2013.09.010.[PubMed 24528911]
Olux (clobetasol) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals, Inc; April 2018.
Olux E (clobetasol) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals, Inc; May 2018.
Olux E (clobetasol) [product monograph]. Dundas, Ontario, Canada: CRI; February 2018.
Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259.[PubMed 19188870]
Temovate cream and ointment (clobetasol) [prescribing information]. Melville, NY: PharmaDerm; January 2018.
Temovate E emollient cream (clobetasol) [prescribing information]. Melville, NY: PharmaDerm; December 2009.
Temovate gel (clobetasol) [prescribing information]. Melville, NY: PharmaDerm; March 2008.
Tovet (clobetasol) [prescribing information]. Fairfield, NJ: Medimetriks Pharmaceuticals; April 2019.
Westermann L, Hügel R, Meier M, et al. Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption. J Dermatol. 2012;39(2):168-171.[PubMed 22379622]
Brand Names: International
Aclobet (BD); Alticort (CL); Befurine (TW); Benate Forte (VN); Betavate (KR); Butavate (GR); Carizon (UA); Clarelux (ES, HR, SK); Clarelux Foam (GB, IE); Clerovate (EG); Clobaderm (MT); Clobasone (TH); Clobenate (PE); Clobesan (ID); Clobeskin (UA); Clobesol (AR, BH, BR, HK, IT, MX); Clobet (TH); Clobex (AU, ES, HK, ID, NZ, PH, SG, SK, TW); Clobexpro (MX); Clobezan (CO, EC); Clobit (LK); Clobitat (EG); Cloderm (AE, BH, CY, ET, HK, IQ, IR, JO, KR, KW, LB, LY, OM, QA, SA, SG, SY, TH, VN, YE); Clofoam (LB); Clonate (MY, PH); Clonovate (SG); Closderm (PH); Clovate (BD, ES, UA); Comclo (JP); Crobate (KR); Cutisone (LK); Decloban (ES); Delor (AE, BH, CY, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, UA, YE); Derbisol (KR); Dermacare (PH); Dermamed (QA); Dermapro (MY); Dermatovate (MX); Dermazone (TH); Dermocare (TW); Dermol (NZ); Dermolin (LK); Dermosol (KR); Dermoval (FR); Dermovat (DK, FI, IS, NO, SE); Dermovate (AE, AT, BB, BD, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CO, CY, CZ, EC, EE, EG, ET, GB, GH, GM, GN, GY, HK, HU, IE, IL, IQ, IR, JM, JO, JP, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, OM, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SG, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, VE, VN, YE, ZM, ZW); Dermoxin (DE); Dhabesol (KR, MY); Dovate (ZA); Eczoria (SK); Elopro (ID); Enderm (ET); Etrivex (GB, IE); Eurobetsol (HK); Exovate (BD); Forderm (ID); Gamavate (QA); Glevate (MY, PH, ZW); Jedcovate (EG); Karison Creme (DE); Karison Salbe (DE); Kloderma (ID); Lobate (IN); Lobesol (MY, SG); Lobevat (MX); Lotasbat (ID); Medodermone (SG, VN); P-Vate (TH); Pentasol (CO); Probelin (PH); Promax (BH); Psorex (BR); Rubocort (GR); S.Z. (TW); Salac (PY); Tempovate (ID); Tenovate (IN); Topifort (IN); Uniderm (HK, KR, TH); Univate (HK, MY); Yihfu (TW)
Last Updated 3/21/20
Google Sites
Report abuse